Kenya

Globally, over 2.1 million adolescents aged 10–19 and 5 million young people aged 15–24 are living with HIV. As a result of greater availability of antiretroviral (ARV) therapy, many infants born with HIV can now survive into adolescence.

Undefined

Overall objective:
To develop a multi-level HIV risk-reduction intervention targeting sex workers and their clients at entertainment venues (bars/night clubs) in Mombasa, Kenya and test its feasibility and acceptability, as well as the feasibility of an intervention evaluation design to be used in a future larger study.

Undefined

Een lespakket en video over wetenschappelijk onderzoek en seksuele en reproductieve gezondheid bij jongeren hier en in het zuiden

Undefined

In Kenya, HPV vaccination is not part of the national immunization scheme. The 2 types of HPV-vaccines are however approved and allowed to use in the country. Dr Hillary Mabeya, National Advisor on Adolescent Vaccination at the Ministry of Health (Kenya), received a grant of 9000 HPV vaccines from the GARDASIL Access Program in order to pilot HPV vaccination. The pilot program started in May 2012 and ended in March 2013. Primary school girls (standard 4 to 9, i.e. approximately 9 to 14 years of age) enrolled in 10 randomly selected public schools were the first target group, but in a second phase the program was opened for young girls from the whole community; 2500 girls of the 3000 girls who received the first dose were fully vaccinated at the end of the program. While vaccination occurred at Moi University Hospital, promotion of the HPV-vaccine was school based: health providers informed teachers who on their turn were asked to inform the girls and parents about the upcoming HPV vaccination opportunity.

Undefined

The Biomarkers Study, short for “Characterisation of Novel Microbicide Safety Biomarkers in East and South Africa”, was initiated with the overall aim of establishing baseline ranges of biomarkers related to the vaginal environment in African target populations for microbicide trials.

Undefined

Determining the prevalence and correlates of placental malaria in HIV1 infected and non-infected women, the effect of placental malaria on viral shedding in the genital tract, and the impact of placental malaria on perinatal HIV1 transmission.

Undefined

In Africa, one out of 210 mothers dies during pregnancy or delivery. One of the causes is the relatively low rate of institutional deliveries, due to transport problems and lack of infrastructure, but also due to cultural prejudices and resistance against giving birth outside the family circle. One of the ways to facilitate and encourage institutional deliveries is the establishment of ‘maternity shelters’ or ‘maternity waiting homes’ (‘casas de espera’ in Portuguese): facilities where future mothers can spend the last few days of their pregnancy close to a maternity hospital, so that they are assured of timely professional care during the delivery. This type of facilities exists in many African countries, but often the functioning is not optimal and the occupancy rate is much lower than it could be. ICRH launched a project in Kenya, aimed at promoting the use of maternity waiting homes and improving their functioning.

Undefined

The main objective is to improve maternal and newborn health through a focus on the postpartum period, adopting context-specific strategies to strengthen health care delivery and services at both facility and community level in four sub-Saharan countries (Burkina Faso, Kenya, Malawi and Mozambique).

Undefined

The DIFFER project aims at improving access to sexual and reproductive health for the most vulnerable by a better linkage between interventions targeted at most-at-risk populations, in particular female sex workers, and the general reproductive health services. It will be implemented at four sites in Kenya (Mombasa), Mozambique (Tete), South Africa (Durban) and India (Mysore).

Undefined

Main objective:
•to strenghten the capacity of two clinical research sites in Africa

Undefined

Pages

Subscribe to Kenya